1
|
Das S, Luu M, Terris M, Klaassen Z, Kane CJ, Amling C, Cooperberg M, Rivera LG, Aronson W, Freedland SJ, Daskivich TJ. Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era. Urol Oncol 2024; 42:175.e1-175.e8. [PMID: 38490923 DOI: 10.1016/j.urolonc.2024.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 02/02/2024] [Accepted: 02/27/2024] [Indexed: 03/17/2024]
Abstract
OBJECTIVES To assess whether contemporary risks of biochemical recurrence (BCR) after radical prostatectomy (RP) in the AS era differ from historical estimates due to changes in tumor risk case mix and improvements in risk stratification. MATERIALS AND METHODS We sampled 6,682 men who underwent RP for clinically localized disease between 2000 and 2017 from the VA SEARCH database. Kaplan Meier analysis was used to calculate incidence of BCR before and after 2010 overall and within tumor risk subgroups. Multivariable Cox proportional hazard regression analysis including an interaction term between era and tumor risk was used to compare risk of BCR before and after 2010 overall and across tumor risk subgroups. RESULTS About 3,492 (52%) and 3,190 (48%) men underwent RP before and after 2010, respectively. In a limited multivariable model excluding tumor risk, overall BCR risk was higher post-2010 vs. pre-2010 (HR: 1.15, 95%CI: 1.05-1.25; 40% vs 36% at 8 years post-RP). However, this effect was eliminated after correcting for tumor risk (HR: 0.95, 95%CI: 0.87-1.04), suggesting that differences in tumor risk between eras mediated the change. Yet, within tumor-risk subgroups, BCR risk was significantly lower for favorable intermediate-risk (HR: 0.76, 95%CI:0.60-0.96) and unfavorable intermediate-risk PC (HR: 0.78, 95%CI: 0.67-0.90), but significantly higher for high-risk PC (HR: 1.22, 95%CI: 1.07-1.38) in the post-2010 era. 8-year risks of BCR in the post-2010 era were 21% (95%CI: 16%-25%), 25% (95%CI: 20%-30%), 41% (95%CI: 37%-46%), and 60% (95%CI: 56%-64%) for low-, FIR-, UIR-, and high-risk disease, respectively. Limitations include limited long-term follow-up in the post-2010 subgroup. CONCLUSIONS Overall BCR risk has increased in the AS era, driven by a higher risk case mix and increased BCR risk among high-risk patients. Physicians should quote contemporary estimates of BCR when counseling patients.
Collapse
Affiliation(s)
- Sanjay Das
- Durham Veterans Affairs Health Care System, Department of Surgery, Durham, NC; Department of Urology, University of California - Los Angeles, Los Angeles, CA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles
| | - Michael Luu
- Department of Biostatistics and Bioinformatics, Cedars-Sinai Medical Center, Los Angeles, CA
| | - Martha Terris
- Division of Urology, Charlie Norwood VA Medical Center, Augusta, GA; Department of Urology, Augusta University-Medical College of Georgia, Augusta, GA
| | - Zachary Klaassen
- Division of Urology, Charlie Norwood VA Medical Center, Augusta, GA; Department of Urology, Augusta University-Medical College of Georgia, Augusta, GA
| | | | | | - Matthew Cooperberg
- Department of Urology, University of California, San Francisco, CA; Section of Urology, San Francisco VA Medical Center, San Francisco, CA
| | - Lourdes Guerrios Rivera
- VA Caribbean Healthcare System, San Juan, PR; Department of Surgery, University of Puerto Rico, San Juan, PR
| | - William Aronson
- Department of Urology, University of California - Los Angeles, Los Angeles, CA; Greater Los Angeles Veterans Affairs, Los Angeles, CA
| | - Stephen J Freedland
- Durham Veterans Affairs Health Care System, Department of Surgery, Durham, NC; Department of Urology, Cedars-Sinai Medical Center, Los Angeles; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
| | - Timothy J Daskivich
- Department of Urology, Cedars-Sinai Medical Center, Los Angeles; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
| |
Collapse
|
2
|
Bergman J, Filippou P, Suskind AM, Johnson K, Calvert E, Fero K, Lorenz KA, Giannitrapani K, Hugar L, Koo K, Leppert J, Scales CD, Terris M, Nielsen M, Gore JL. Primary Palliative Care in Urology: Quality Improvement Summit 2021-2022. Urol Pract 2024; 11:529-536. [PMID: 38451199 DOI: 10.1097/upj.0000000000000538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 01/19/2024] [Indexed: 03/08/2024]
Abstract
INTRODUCTION The AUA convened a 2021-2022 Quality Improvement Summit to bring together interdisciplinary providers to inform the current state and to discuss potential strategies for integrating primary palliative care into urology practice. We hypothesized that the Summit findings would inform a scalable primary palliative care model for urology. METHODS The 3-part summit reached a total of 160 interdisciplinary health care professionals. Webinar 1, "Building a Primary Palliative Care Model for Urology," focused on a urologist's role in palliative care. Webinar 2, "Perspectives on Increasing the Use of Palliative Care in Advanced Urologic Disease," addressed barriers to possible implementation of a primary palliative care model. The in-person Summit, "Laying the Foundation for Primary Palliative Care in Urology," focused on operationalization of primary palliative care, clinical innovations needed, and relevant metrics. RESULTS Participants agreed that palliative care is needed early in the disease course for patients with advanced disease, including those with benign and malignant conditions. The group agreed about the important domains that should be addressed as well as the interdisciplinary providers who are best suited to address each domain. There was consensus that a primary "quarterback" was needed, encapsulated in a conceptual model-UroPal-with a urologist at the hub of care. CONCLUSIONS The Summit provides the field of urology with a framework and specific steps that can be taken to move urology-palliative care integration forward. Urologists are uniquely positioned to provide primary palliative care for their many patients with serious illness, both in the surgical and chronic care contexts.
Collapse
Affiliation(s)
- Jonathan Bergman
- The David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California
- Los Angeles County Department of Health Services, Los Angeles, California
- Veterans Health Administration, Los Angeles, California
| | - Pauline Filippou
- Kaiser Permanente Northern California, Santa Clara Medical Center, Santa Clara, California
| | - Anne M Suskind
- University of California, San Francisco, San Francisco, California
| | - Karen Johnson
- American Urological Association, Linthicum, Maryland
| | - Emily Calvert
- American Urological Association, Linthicum, Maryland
| | - Katherine Fero
- The David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California
| | - Karl A Lorenz
- Veterans Health Administration, Los Angeles, California
- Stanford University, Stanford, California
| | - Karleen Giannitrapani
- Veterans Health Administration, Los Angeles, California
- Stanford University, Stanford, California
| | - Lee Hugar
- Lexington Medical Center, West Columbia, South Carolina
| | | | - John Leppert
- Veterans Health Administration, Los Angeles, California
- Stanford University, Stanford, California
| | | | | | - Matthew Nielsen
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - John L Gore
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| |
Collapse
|
3
|
Cabo JJS, Koch GE, Tallman JE, Thavaseelan S, Oberle M, Terris M, Kronenberg DG, Buckley JC, Scarpato KR, Chang SS. The Role of Alumni Networks and Career Advising in Early Career Stability of Urologists: Results of a Multi-institutional Study. Urology 2023; 182:48-54. [PMID: 37716454 DOI: 10.1016/j.urology.2023.08.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 07/06/2023] [Accepted: 08/01/2023] [Indexed: 09/18/2023]
Abstract
OBJECTIVE To characterize training program and early career factors that impact decision-making and job retention following graduation in a diverse population of urologists. MATERIALS AND METHODS We performed a computer-based survey distributed to residency graduates from 25 urology training programs. Five focus institutions were identified with a goal >30% response rate. The survey included questions about training program specifics and post-training employment characteristics. RESULTS We obtained 180 responses from urology residency graduates of 25 programs. Overall, 72% (N = 129) remain in their initial post-training position at a median of 6years postgraduation (Interquartile Range (IQR) 3-10). On Cox-regression analysis stronger trainee-rated formal career advising was associated with lower risk of changing jobs (HR 0.77, 0.60-0.99, P = .048). Location/proximity to family was the most consistently cited as the top reason for selecting a job (41%). Sixty-three respondents (35%) joined practices employing graduates of the same residency program. Cox regression analysis showed that joining a practice with alumni of the same program was associated with lower risk of changing jobs from one's initial post-training position (HR 0.39, 95% CI 0.17-0.91, P = .03). CONCLUSION In this multi-institutional study of urologists, we observed a high rate of job retention out to a median of 6years following completion of training, with formal career advising and joining alumni in practice being associated with job retention. Collectively, our data highlights that training programs should emphasize advising programs and alumni networking in guiding their graduates in the job search process.
Collapse
Affiliation(s)
- Jackson J S Cabo
- Department of Urology, Vanderbilt University Medical Center, Nashville, TN.
| | - George E Koch
- Department of Urology, Vanderbilt University Medical Center, Nashville, TN
| | - Jacob E Tallman
- Department of Urology, Vanderbilt University Medical Center, Nashville, TN
| | | | - Michael Oberle
- Department of Urology, Medical College of Georgia, Augusta University, Augusta, GA
| | - Martha Terris
- Department of Urology, Medical College of Georgia, Augusta University, Augusta, GA
| | | | - Jill C Buckley
- Department of Urology, University of California, San Diego, San Diego, CA
| | - Kristen R Scarpato
- Department of Urology, Vanderbilt University Medical Center, Nashville, TN
| | - Sam S Chang
- Department of Urology, Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
4
|
Chen MS, Howard LE, Stock S, Dolgner A, Freedland SJ, Aronson W, Terris M, Klaassen Z, Kane C, Amling C, Cooperberg M, Daskivich TJ. Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy. Prostate Cancer Prostatic Dis 2023; 26:715-721. [PMID: 35668181 DOI: 10.1038/s41391-022-00550-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 03/17/2022] [Accepted: 04/22/2022] [Indexed: 11/09/2022]
Abstract
PURPOSE Accurate prediction of competing risks of mortality remains a key component of prostate cancer treatment decision-making. We sought to validate the Prostate Cancer Comorbidity Index (PCCI) score for predicting other-cause mortality (OCM) and cancer outcomes in men undergoing radical prostatectomy (RP). MATERIALS AND METHODS We sampled 4857 men with prostate cancer treated with RP in the VA from 2000-2018. Risks of OCM, 90-day all-cause mortality (ACM), prostate cancer-specific mortality, metastasis, and biochemical recurrence by PCCI score were assessed using Cox proportional hazards and logistic regression. We compared prediction of 90-day ACM between PCCI and the American Society of Anesthesiology (ASA) score, a validated predictor of short-term mortality. RESULTS Over median follow-up of 6.7 years (IQR 3.7-10.3), there was a stepwise increase in risk of OCM with higher PCCI score, with hazards (95%CI) of 1.53 (1.14-2.04), 2.11 (1.55-2.88), 2.36 (1.68-3.31), 3.61 (2.61-4.98), and 4.99 (3.58-6.96) for PCCI 1-2, 3-4, 5-6, 7-9, and 10 + (vs. 0), respectively. Projected 10-year cumulative incidence of OCM was 8%, 12%, 16%, 19%, 26%, and 32% for scores of 0, 1-2, 3-4, 5-6, 7-9, and 10+ , respectively. Men with PCCI 7+ had greater odds of 90-day ACM (OR 3.48, 95%CI 1.26-9.63) while men with higher ASA did not. Higher PCCI score was associated with worse cancer outcomes, with the highest categories driving the associations. CONCLUSIONS The PCCI is a robust measure of short- and long-term OCM after RP, validated for use in clinical care and health services research focusing on surgical patient populations.
Collapse
Affiliation(s)
- Michelle S Chen
- University of California, San Diego School of Medicine, La Jolla, CA, USA
| | - Lauren E Howard
- Section of Urology, Durham VA Medical Center, Durham, NC, USA
- Department of Urology, Duke University, Durham, NC, USA
| | - Shannon Stock
- Section of Urology, Durham VA Medical Center, Durham, NC, USA
- Department of Mathematics and Computer Science, College of the Holy Cross, Worcester, MA, USA
| | | | - Stephen J Freedland
- Section of Urology, Durham VA Medical Center, Durham, NC, USA
- Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - William Aronson
- Division of Urology, West Los Angeles VA Medical Center, Los Angeles, CA, USA
- Department of Urology, UCLA Medical Center, Los Angeles, CA, USA
| | - Martha Terris
- Divison of Urology, Charlie Norwood VA Medical Center, Augusta, GA, USA
- Division of Urology, Department of Surgery, Augusta University-Medical College of Georgia, Augusta, GA, USA
| | - Zachary Klaassen
- Divison of Urology, Charlie Norwood VA Medical Center, Augusta, GA, USA
- Division of Urology, Department of Surgery, Augusta University-Medical College of Georgia, Augusta, GA, USA
| | - Christopher Kane
- Department of Urology, University of California, San Diego, CA, USA
| | - Christopher Amling
- Department of Urology, Oregon Health Sciences University, Portland, OR, USA
| | - Matthew Cooperberg
- Department of Urology, University of California, San Francisco, CA, USA
- Section of Urology, San Francisco VA Medical Center, San Francisco, CA, USA
| | - Timothy J Daskivich
- Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
| |
Collapse
|
5
|
Stabellini N, Cullen J, Bittencourt MS, Moore JX, Cao L, Weintraub NL, Harris RA, Wang X, Datta B, Coughlin SS, Garcia J, Shanahan J, Hamerschlak N, Waite K, Fillmore NR, Terris M, Montero AJ, Barnholtz-Sloan JS, Guha A. Allostatic load and cardiovascular outcomes in males with prostate cancer. JNCI Cancer Spectr 2023; 7:7031248. [PMID: 36752520 PMCID: PMC10005613 DOI: 10.1093/jncics/pkad005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 12/23/2022] [Accepted: 02/01/2023] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND Cardiovascular disease (CVD) is the leading cause of death in men with prostate cancer (PC). Accumulated stress plays an important role in CVD development. The cumulative burden of chronic stress and life events can be measured using allostatic load (AL). METHODS The initial cohort included males aged 18 years and older diagnosed with PC (2005-2019). AL was modeled as an ordinal variable (0-11). Fine-Gray competing risk regressions measured the impact of precancer diagnosis AL and postdiagnosis AL in 2-year major cardiac events (MACE). The effect of AL changes over time on MACE development was calculated via piecewise Cox regression (before, and 2 months, 6 months, and 1 year after PC diagnosis). RESULTS We included 5261 PC patients of which 6.6% had a 2-year MACE. For every 1-point increase in AL before and within 60 days after PC diagnosis, the risk of MACE increased 25% (adjusted hazard ratio [aHR] =1.25, 95% confidence interval [CI] = 1.18 to 1.33) and 27% (aHR = 1.27, 95% CI = 1.20 to 1.35), respectively. Using AL as a time-varying exposure, the risk of MACE increased 19% (aHR = 1.19, 95% CI = 1.11 to 1.27), 22% (aHR = 1.22, 95% CI = 1.14 to 1.33), 28% (aHR = 1.28, 95% CI = 1.23 to 1.33), and 31% (aHR = 1.31, 95% CI = 1.27 to 1.35) for every 1-point increase in AL before, 2 months after, 6 months after, and 1 year after PC diagnosis, respectively. CONCLUSION AL and its changes over time are associated with MACE in PC patients, suggesting a role of a biological measure of stress as a marker of CVD risk among men with PC.
Collapse
Affiliation(s)
- Nickolas Stabellini
- Graduate Education Office, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Department of Hematology-Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.,Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.,Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Jennifer Cullen
- Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA
| | - Marcio S Bittencourt
- Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
| | - Justin X Moore
- Cancer Prevention, Control, & Population Health Program, Department of Medicine, Medical College of Georgia at Augusta University, GA, USA
| | - Lifen Cao
- Department of Hematology-Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA
| | - Neal L Weintraub
- Department of Medicine, Cardiology Division, Medical College of Georgia at Augusta University, Augusta, GA, USA.,Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA, USA
| | - Ryan A Harris
- Department of Medicine, Georgia Prevention Institute, Augusta University, Augusta, GA, USA.,Sport and Exercise Science Research Institute, Ulster University, Jordanstown, Northern Ireland, UK
| | - Xiaoling Wang
- Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA
| | - Biplab Datta
- Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA, USA.,Institute of Public and Preventive Health, Augusta University, Augusta, GA, USA
| | - Steven S Coughlin
- Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA, USA.,Institute of Public and Preventive Health, Augusta University, Augusta, GA, USA
| | - Jorge Garcia
- Department of Hematology-Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA
| | - John Shanahan
- Cancer Informatics, Seidman Cancer Center at University Hospitals of Cleveland, Cleveland, OH, USA
| | - Nelson Hamerschlak
- Oncohematology Department, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
| | - Kristin Waite
- Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Nathanael R Fillmore
- Cooperative Studies Program (CSP) Informatics Center, Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Martha Terris
- Urology Section, Department of Surgery, Veterans Affairs Medical Centers, Augusta, GA, USA.,Division of Urologic Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA, USA
| | - Alberto J Montero
- Department of Hematology-Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA
| | - Jill S Barnholtz-Sloan
- Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.,Center for Biomedical Informatics and Information Technology (CBIIT), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Avirup Guha
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Cardio-Oncology Program, Ohio State University, OH, USA.,Cardio-Oncology Program, Department of Medicine, Cardiology Division, Medical College of Georgia, Augusta University, Augusta, GA, USA
| |
Collapse
|
6
|
Swaby J, Aggarwal A, Batra A, Jain A, Seth L, Stabellini N, Bittencourt MS, Leong D, Klaassen Z, Barata P, Sayegh N, Agarwal N, Terris M, Guha A. Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis. Clin Genitourin Cancer 2022; 21:e182-e189. [PMID: 36621463 DOI: 10.1016/j.clgc.2022.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 12/15/2022] [Accepted: 12/21/2022] [Indexed: 12/27/2022]
Abstract
BACKGROUND Androgen deprivation therapy (ADT), a backbone treatment for advanced prostate cancer (PC), is known to have a variety of metabolic side effects. We conducted an updated meta-analysis to quantify the metabolic risks of ADT. MATERIALS AND METHODS We searched PubMed, Web of Science, and Scopus in May of 2022 for studies investigating the risk of metabolic syndrome (MetS), diabetes, and hypertension from ADT in PC patients using keywords. Only full-length studies with a control group of PC patients not on ADT were included. All results compatible with each outcome domain in each included study were sought. For included studies, relative risk (RR) was pooled using a random effects model and a trim-fill approach was used to adjust for publication bias. RESULTS 1,846 records were screened, of which 19 were found suitable for data extraction. Five studies, including 891 patients, were evaluated for MetS as an outcome, with the random effects model showing a pooled RR of 1.60 ([95% Confidence Interval (CI), 1.06-2.42]; P=0.03) for patients on ADT while twelve studies, including 336,330 patients, examined diabetes as an outcome, and the random effects model showed a RR of 1.43 ([95% CI, 1.28-1.59]; P< 0.01). After adjustment for publication bias, ADT was associated with a 25% increased risk for diabetes but was not associated with MetS. 4 studies, including 7,051 patients, examined hypertension as an outcome, and the random effects model showed a RR of 1.30 ([95% CI, 1.08-1.55]; P=0.18) in ADT patients. CONCLUSION In patients with PC, ADT was not associated with MetS and the association with diabetes was not as strong as previously reported. Our novel meta-analysis of hypertension showed that ADT increased the risk of hypertension by 30%. These results should be understood in the context of collaborating care between a patient's oncologist and primary care provider to optimize care.
Collapse
Affiliation(s)
- Justin Swaby
- Department of Cardiovascular Disease, Augusta University, Augusta, GA
| | | | - Akshee Batra
- Department of Internal Medicine, University of Vermont, Burlington, VT
| | - Anubhav Jain
- Department of Cardiology, Ascension Genesys Hospital, Garden city, MI
| | - Lakshya Seth
- Department of Cardiovascular Disease, Augusta University, Augusta, GA
| | - Nickolas Stabellini
- Department of Hematology- Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH
| | | | - Darryl Leong
- Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Canada
| | | | - Pedro Barata
- Genitourinary Medical Oncology, Tulane University Medical School, New Orleans, LA
| | | | | | - Martha Terris
- Division of Surgery: Urology, Augusta University, Augusta, GA
| | - Avirup Guha
- Department of Cardiovascular Disease, Augusta University, Augusta, GA.
| |
Collapse
|
7
|
Reddy KRK, Park JH, Bollag RJ, Bellman A, Terris M, Lerner SP, Ballester LY, Lotan Y, Kaipparettu BA, Putluri N. Abstract 3771: Mitochondrial metabolism and racial disparity of bladder cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Potential differences and mechanism in metabolism among bladder cancer (BLCA) patients of diverse race or ethnicities remain largely unexplored. Even though the incidence rate of BLCA in African Americans (AA) is nearly half as that of European Americans (EA), but AA have the worst survival. We performed the transcriptomics and metabolomics profiling in ancestry verified patients from AA and EA BLCA and observed mitochondrial complex activities were uniquely enriched in AA tumors compared to EA tumors. In addition, in vitro assay demonstrated differences in mitochondrial complex protein and activity between AA and EA BLCA. We further confirmed the reprogramming of mitochondrial metabolism using in vitro 13C labeled tracers in both AA and EA BLCA. Integration of metabolomics and transcriptomics data reveals the enrichment of mTOR pathway in AA BLCA. Our findings indicate that an elevated mitochondrial oxphos activity through mTOR activation could be a factor for AA BLCA progression and provide the rationale to examine mitochondrial specific inhibitors along with mTOR inhibitors to target BLCA on subset of patients from the AA community.
Citation Format: Karthik Reddy Kami Reddy, Jun Hyoung Park, Roni J. Bollag, Allison Bellman, Martha Terris, Seth P. Lerner, Leomar Y. Ballester, Yair Lotan, Benny Abraham Kaipparettu, Nagireddy Putluri. Mitochondrial metabolism and racial disparity of bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3771.
Collapse
Affiliation(s)
| | | | | | - Allison Bellman
- 3The University of Texas Health Science Center at Houston, Houston, TX
| | | | | | | | - Yair Lotan
- 5UT southwestern Medical center, Dallas, TX
| | | | | |
Collapse
|
8
|
Morton M, Omar N, Madi R, Terris M, Powell M. Collision metastasis: Renal cell carcinoma and prostatic adenocarcinoma to a retroperitoneal lymph node. Urol Case Rep 2021; 40:101884. [PMID: 34712581 PMCID: PMC8531555 DOI: 10.1016/j.eucr.2021.101884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Accepted: 10/11/2021] [Indexed: 11/18/2022] Open
Abstract
Prostatic adenocarcinoma and renal cell carcinoma (RCC) can coexist. However, the incidence of collision metastasis of both prostatic adenocarcinoma and RCC is a rare phenomenon. A 50-year-old non-smoker male with end stage renal disease and a history of prostate adenocarcinoma was noted to have a left renal mass in the upper pole during CT surveillance. With the use of immunohistochemical stains the collision of two distinct malignancies from two different topographical regions was elucidated in a retroperitoneal lymph node. We report the second known case of collision metastasis of RCC and prostatic adenocarcinoma to a retroperitoneal lymph node. Collision metastasis of renal cell carcinoma and prostatic adenocarcinoma is rare. It is important to keep a high index of suspicion for collision metastasis. Immunohistochemistry can confirm collision metastasis of a suspicious lymph node.
Collapse
Affiliation(s)
| | - Nivin Omar
- Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, USA
| | - Rabii Madi
- Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA, USA
- Georgia Cancer Center, Augusta, GA, USA
| | - Martha Terris
- Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA, USA
- Georgia Cancer Center, Augusta, GA, USA
| | - Matthew Powell
- Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, USA
- Corresponding author.
| |
Collapse
|
9
|
Vaculik K, Luu M, Howard LE, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ, Daskivich TJ. Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. JAMA Netw Open 2021; 4:e2112214. [PMID: 34081138 PMCID: PMC8176332 DOI: 10.1001/jamanetworkopen.2021.12214] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
IMPORTANCE Guidelines endorse using tumor risk and life expectancy (LE) to select appropriate candidates for radical prostatectomy (RP), recommending against treatment of most low-risk tumors and men with limited LE. OBJECTIVE To investigate time trends in the use of RP by tumor risk and Prostate Cancer Comorbidity Index (PCCI) score in a contemporary, nationally representative Veterans Affairs (VA) cohort. DESIGN, SETTING, AND PARTICIPANTS This cohort study of 5736 men treated with RP at 8 VA hospitals from January 1, 2000, to December 31, 2017, used a nationally representative, multicenter sample from the VA SEARCH (Shared Equal Access Regional Cancer Hospital) database. Statistical analysis was performed from June 30, 2018, to August 20, 2020. MAIN OUTCOMES AND MEASURES Stratified linear and log-linear Poisson regressions were used to estimate time trends in the proportion of men treated with RP across American Urological Association tumor risk and PCCI (a validated predictor of LE based on age and comorbidities) subgroups. RESULTS Among 5736 men (mean [SD] age at surgery, 62 [6] years) treated with RP from 2000 to 2017, the proportion of low-risk tumors treated with RP decreased from 51% to 7% (difference, -44%; 95% CI, -50% to -38%). The proportion of intermediate-risk tumors treated with RP increased from 30% to 59% (difference, 29%; 95% CI, 23%-35%), with unfavorable intermediate-risk tumors increasing from 30% to 41% (difference, 11%; 95% CI, 4%-18%) and favorable intermediate-risk tumors decreasing from 61% to 41% (difference, -20%; 95% CI, -24% to -15%). The proportion of high-risk tumors treated with RP increased from 18% to 33% (difference, 15%; 95% CI, 9%-21%). Among men treated with RP, the proportion with the highest PCCI scores of 10 or more (ie, LE <10 years) increased from 4% to 13% (difference, 9%; 95% CI, 4%-14%). Within each tumor risk subgroup, no significant difference in the rate of tumors treated with RP over time was found across PCCI subgroups. CONCLUSIONS AND RELEVANCE In this study, the use of RP shifted from low-risk and favorable intermediate-risk to higher-risk prostate cancer. However, its use among men with limited LE appears unchanged across tumor risk subgroups and increased overall.
Collapse
Affiliation(s)
- Kristina Vaculik
- Los Angeles County Department of Public Health, Los Angeles, California
- Cedars-Sinai Center for Outcomes Research and Education, Los Angeles, California
| | - Michael Luu
- Divison of Urology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Lauren E. Howard
- Section of Urology, Durham Veterans Affairs Medical Center, Durham, North Carolina
| | - William Aronson
- Division of Urology, West Los Angeles Veterans Affairs Medical Center, Los Angeles, California
- Department of Urology, University of California at Los Angeles School of Medicine, Los Angeles
| | - Martha Terris
- Divison of Urology, Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia
- Section of Urology, Medical College of Georgia, Augusta
| | - Christopher Kane
- Urology Department, University of California at San Diego Health System, San Diego
| | | | - Matthew Cooperberg
- Department of Urology, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - Stephen J. Freedland
- Divison of Urology, Cedars-Sinai Medical Center, Los Angeles, California
- Section of Urology, Durham Veterans Affairs Medical Center, Durham, North Carolina
| | - Timothy J. Daskivich
- Cedars-Sinai Center for Outcomes Research and Education, Los Angeles, California
- Divison of Urology, Cedars-Sinai Medical Center, Los Angeles, California
| |
Collapse
|
10
|
Vaculik K, Luu M, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland S, Daskivich* T. MP54-14 TIME TRENDS IN USE OF RADICAL PROSTATECTOMY BY TUMOR RISK AND LIFE EXPECTANCY IN A NATIONAL VA COHORT FROM 2000 TO 2017. J Urol 2019. [DOI: 10.1097/01.ju.0000556681.16460.b3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Sellman DP, Peard L, Simpson G, Lancaster K, Kavuri S, Terris M, Madi R. Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder. Urol Ann 2018; 10:342-344. [PMID: 30089999 PMCID: PMC6060602 DOI: 10.4103/ua.ua_97_17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%–28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.
Collapse
Affiliation(s)
- David P Sellman
- Section of Urology, Medical College of Georgia - Augusta University, Augusta, GA, USA
| | - Leslie Peard
- Section of Urology, Medical College of Georgia - Augusta University, Augusta, GA, USA
| | - Greg Simpson
- Section of Urology, Medical College of Georgia - Augusta University, Augusta, GA, USA
| | - Katrina Lancaster
- Section of Urology, Medical College of Georgia - Augusta University, Augusta, GA, USA
| | - Sravan Kavuri
- Section of Urology, Medical College of Georgia - Augusta University, Augusta, GA, USA
| | - Martha Terris
- Section of Urology, Medical College of Georgia - Augusta University, Augusta, GA, USA
| | - Rabbi Madi
- Department of Surgery, Medical College of Georgia - Augusta University, Augusta, GA, USA
| |
Collapse
|
12
|
Branche B, Howard L, Hamilton R, Aronson W, Terris M, Cooperberg M, Amling C, Kane C, Freedland S. MP34-11 OBESITY, RISK OF BIOCHEMICAL RECURRENCE, AND PSADT AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Allott E, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland S. MP87-07 STATIN USE IS ASSOCIATED WITH IMPROVED PROSTATE CANCER-SPECIFIC OUTCOMES IN WHITE BUT NOT BLACK MEN INITIATING ANDROGEN DEPRIVATION THERAPY. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.2907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Sayyid R, Ahmad A, Leao R, Klaassen Z, Madi R, Terris M, Belew D, Bhindi B, Goldberg H, Chandrasekar T, Perlis N, Fleshner N. PD59-08 METFORMIN USE IS ASSOCIATED WITH IMPROVED INTERNATIONAL PROSTATE SYMPTOM SCORES IN MEN WITH METABOLIC SYNDROME. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.2808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
15
|
Moghanaki D, Howard L, De Hoedt A, Aronson W, Kane C, Amling C, Cooperberg M, Terris M, Freedland S. PD14-10 VALIDITY OF THE NATIONAL DEATH INDEX TO ACCURATELY CODE THE DATE OF DEATH AND DEATHS FROM PROSTATE CANCER, IN MEN HAVING UNDERGONE PROSTATECTOMY. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Moradzadeh A, Howard L, Aronson W, Terris M, Cooperberg M, Amling C, Kane C, Freedland S, Daskivich T. MP51-13 THE IMPACT OF COMORBIDITY AND AGE ON TIMING OF ANDROGEN DEPRIVATION THERAPY IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Belew D, Morera D, Lahorewala S, Jordan A, Klaassen Z, Terris M, Soloway M, Lokeshwar V. MP58-01 MOLECULAR SUBTYPES IN MUSCLE INVASIVE BLADDER CANCER: EVALUATION OF CLINICAL SIGNIFICANCE. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.1833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Schulman A, Howard L, Tay KJ, Gupta R, Tsivian E, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Freedland S, Polascik T. PD10-11 ANALYSIS OF THE PREDICTIVE UTILITY OF PROGNOSTIC GRADE GROUPS (PGG) FOR PREDICTING PERIOPERATIVE ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY IN THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
19
|
Teeter A, Sun X, Howard L, Aronson W, Kane C, Amling C, Cooperberg M, Terris M, Freedland S. PD40-12 DO SICKER PEOPLE HAVE WORSE PROSTATE CANCER-SPECIFIC OUTCOMES AFTER RADICAL PROSTATECTOMY? RESULTS FROM SEARCH. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
20
|
Whitney C, Howard L, Freedland S, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Daskivich T. PD03-08 IMPACT OF AGE, COMORBIDITY, AND PSA DOUBLING TIME ON LONG-TERM COMPETING RISKS FOR MORTALITY AMONG MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Whitney C, Howard L, Posadas E, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Freedland S. PD24-09 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER VISCERAL METASTASES PREDICTS SHORTER OVERALL SURVIVAL: WHAT PREDICTS VISCERAL METASTASES? RESULTS FROM THE SEARCH DATABASE. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Zumsteg Z, Chen Z, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Spratt D, Sandler H, Freedland S. MP20-02 NOVEL RISK STRATIFICATION GROUPING USING STANDARD CLINICAL AND BIOPSY INFORMATION FOR PATIENTS UNDERGOING RADICAL PROSTATECTOMY: RESULTS FROM SEARCH. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
23
|
Teeter A, Griffin K, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland S. PD40-07 DOES EARLY PSADT (EPSADT) AFTER RADICAL PROSTATECTOMY, CALCULATED PRIOR TO PSA RECURRENCE, CORRELATE WITH PROSTATE CANCER (PC) OUTCOMES? RESULTS FROM THE SEARCH DATABASE. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1747] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Stroup S, Moreira D, Chen Z, Howard L, Terris M, Aronson W, Cooperberg M, Amling C, Kane C, Freedland S. MP09-18 BIOPSY-DETECTED GLEASON PATTERN 5 IS A PARTICULARLY STRONG PREOPERATIVE PREDICTOR OF RECURRENCE, METASTASIS, AND MORTALITY IN MEN WITH HIGH-RISK PROSTATE CANCER. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Walker K, Amling C, Carroll P, Cooperberg M. PD42-03 PATHOLOGIC AND BIOCHEMICAL OUTCOMES AMONG AFRICAN-AMERICAN AND CAUCASIAN MEN WITH LOW-RISK PROSTATE CANCER IN THE SEARCH DATABASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE CANDIDACY. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.1755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Whitney C, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Freedland S. S&T-12 RACE DOES NOT PREDICT THE DEVELOPMENT OF METASTASES IN MEN WITH NON-METASTATIC CASTRATE RESISTANT PROSTATE CANCER. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Stroup S, Chen Z, Howard L, Freedland S, Moreira D, Terris M, Aronson W, Cooperberg M, Amling C, Kane C. MP79-15 RADICAL PROSTATECTOMY AND THE EFFECT OF CLOSE SURGICAL MARGINS: ANALYSIS FROM THE SEARCH DATABASE. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Moreira D, Howard L, Hanyok B, Kadiyala V, Kuang J, Whitney C, Wilks F, Kane C, Terris M, Amling C, Cooperberg M, Aronson W, Freedland S. MP50-13 VALIDATION OF A BONE SCAN POSITIVITY RISK TABLE IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
McGinley K, Howard L, Chen Z, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland S. PD43-02 ARE WE OPERATING ON WHO WE SHOULD? THE CHANGING CHARACTERISTICS OF RADICAL PROSTATECTOMY PATIENTS: RESULTS FROM THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.1780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
Campbell J, Zhao J, Zaenger D, Colton L, Madi R, Dasher B, Ferguson C, Lewis R, Smith A, Sadek R, Terris M, Kong F. No Significant Difference in Overall Survival between Caucasian and African Americans Patient With Prostate Cancer: An Analysis of 1338 Patients From a Single Institution. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Fischer S, Simon R, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland S, Vidal A. MP4-17 PATHOLOGIC GLEASON 8-10: DO ALL MEN DO POORLY? RESULTS FROM THE SEARCH DATABASE. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Hanyok B, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Freedland S. MP87-09 WHEN IS AN EQUIVOCAL BONE SCAN NOT REALLY EQUIVOCAL? RESULTS FROM SEARCH. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.1954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Hanyok B, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Freedland S. MP87-08 IS COMPUTERIZED TOMOGRAPHY A NECESSARY PART OF A PROSTATE CANCER METASTATIC WORKUP? RESULTS FROM SEARCH. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.1953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Wadhwa H, Terris M, Aronson W, Kane C, Amling C, Cooperberg M, Freedland S, Abern M. MP53-12 LONG TERM ONCOLOGICAL OUTCOMES OF APICAL POSITIVE SURGICAL MARGINS AT RADICAL PROSTATECTOMY IN THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) COHORT. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.1706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Simon R, Howard L, Freedland S, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Vidal A. PD38-11 ADVERSE PATHOLOGY YET UNDETECTABLE ULTRASENSITIVE PSA: IS ADJUVANT RADIATION REALLY NECESSARY? J Urol 2015. [DOI: 10.1016/j.juro.2015.02.2432] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
Moreira D, Howard L, Sourbeer K, Kundich R, Kane C, Aronson W, Terris M, Cooperberg M, Amling C, Freedland S. MP78-03 PREDICTORS OF TIME TO METASTASIS IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. J Urol 2014. [DOI: 10.1016/j.juro.2014.02.2486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
37
|
Moreira D, Presti J, Aronson W, Terris M, Kane C, Amling C, Freedland S. 964 CIGARETTE SMOKING IS ASSOCIATED WITH SHORTER TIME FROM RADICAL PROSTATECTOMY TO METASTASIS: RESULTS FROM THE SEARCH DATABASE. J Urol 2013. [DOI: 10.1016/j.juro.2013.02.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Stroup S, Moreira D, Gerber L, Freedland S, Millard F, Terris M, Aronson W, Presti J, Amling C, Kane C. 366 BIOPSY-DETECTED GLEASON PATTERN 5 PREDICTS RECURRENCE IN MEN WITH HIGH-RISK PROSTATE CANCER. J Urol 2013. [DOI: 10.1016/j.juro.2013.02.1754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Muller R, Moreira D, Aronson W, Terris M, Kane C, Amling C, Presti J, Freedland S. 719 SALVAGE RADIATION THERAPY AFTER RECURRENT PROSTATE CANCER: HOW EARLY DO WE NEED TO BE ? J Urol 2013. [DOI: 10.1016/j.juro.2013.02.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Chu D, Moreira D, Gerber L, Presti J, Aronson W, Terris M, Kane C, Amling C, Freedland S. 64 THE EFFECT OF RACE AND SOCIOECONOMIC STATUS ON SURGICAL MARGINS AND BIOCHEMICAL OUTCOMES IN AN EQUAL-ACCESS HEALTHCARE SETTING: RESULTS FROM THE SEARCH DATABASE. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Muller R, Presti J, Aronson W, Terris M, Kane C, Amling C, Freedland S. 1465 DOES SALVAGE RADIATION THERAPY CHANGE THE BIOLOGY OF RECURRENT PROSTATE CANCER BASED ON PSA DOUBLING TIMES? RESULTS FROM THE SEARCH DATABASE. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.1986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Abern M, Freedland S, Aronson W, Terris M, Presti J, Kane C, Amling C. 997 DELAYED RADICAL PROSTATECTOMY IN GLEASON 7 PROSTATE CANCER DECREASES TIME TO BIOCHEMICAL RECURRENCE: RESULTS FROM THE SEARCH DATABASE. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.1098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Moreira D, Banez L, Aronson W, Presti J, Terris M, Kane C, Amling C, Freedland S. 679 LOW SERUM FOLATE IS A RISK FACTOR FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY RESULTS FROM THE SEARCH DATABASE. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Singh A, Freedland S, Gerber L, Aronson W, Terris M, Presti J, Amling C, Kane C, Banez LL. 360 SHOULD CLINICAL STAGE T2C PROSTATE CANCER BE CLASSIFIED AS INTERMEDIATE- OR HIGH-RISK? - RESULTS FROM THE SEARCH DATABASE. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Punnen S, Freedland S, Presti J, Kane C, Amling C, Terris M, Aaronson W, Carroll P, Cooperberg M. 162 MULTI-INSTITUTIONAL VALIDATION OF THE CAPRA-S SCORE TO PREDICT OUTCOMES AFTER RADICAL PROSTATECTOMY. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
46
|
Kopp R, Stroup S, Gerber L, Freedland S, Terris M, Aronson W, Presti J, Amling C, Kane C. 338 DO REPEATED PROSTATE BIOPSIES WORSEN THE OUTCOME AMONG MEN WITH PROSTATE CANCER WHO HAVE A RADICAL PROSTATECTOMY? RESULTS FROM THE SEARCH DATABASE. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Moreira D, Presti J, Aronson W, Terris M, Kane C, Amling C, Freedland S. 902 PREDICTORS OF PROSTATE CANCER-SPECIFIC MORTALITY IN PATIENTS WITH RESIDUAL DISEASE AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.2611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Moreira D, Presti J, Aronson W, Terris M, Kane C, Amling C, Freedland S. 1464 EXTRACAPSULAR EXTENSION PREDICTS LATE RECURRENCE IN PATIENTS WHO ACHIEVE UNDETECTABLE PSA AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.1399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
49
|
Teeter A, Aronson W, Presti J, Terris M, Amling C, Kane C, Freedland S. 2060 DOES PSA DOUBLING TIME AFTER RADICAL PROSTATECTOMY CORRELATE WITH OVERALL SURVIVAL? A REPORT FROM THE SEARCH DATABASE GROUP. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.2107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Rhee A, Reid-Nicholson M, Motiwala N, Drury S, Peiper S, Waller J, Ramalingham P, Terris M. 629 CAN THE CHROMOSOMAL ABNORMALITIES IN RENAL CELL CARCINOMA RESULT IN A POSITIVE UROVYSION™ FLUORESCENCE IN SITU HYBRIDIZATION AND REVEAL RENAL TUMOR CHARACTERISTICS? J Urol 2010. [DOI: 10.1016/j.juro.2010.02.965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|